Postdoc’ing in Andrew Wang’s Lab Yale internal Medicine: Rheumatology | former UConn Health PhD candidate - Rathinam Lab | Former postgrad in the Wilen Lab at Yale | RNA is life
Vincent Graziano
Loading...
Huge advance in glycoRNA biology. Congrats to @raflynn5.bsky.social and all of the wonderful authors! Can’t wait to see what you guys do next!
Vincent Graziano
Don’t trust the experts”? That’s not democracy, that’s recklessness.
On a plane, I want a pilot.
In a hospital, I want doctors and scientists who understand the evidence.
Expertise isn’t religion or authoritarianism — it’s training, accountability, and data.
Ignore it and we all pay the price.
Sugar coats shield immunogenic RNA modification:A new function for RNA glycosylation: Molecular Cell www.cell.com/molecular-ce... @raflynn5.bsky.social @vinnieviruses.bsky.social
A new function of glycosylated RNAs has been discovered by Graziano et al. in which
the glycosylation of RNA molecules shields acp³U RNA modification from triggering
innate immune responses.
In our latest episode, @woodrufflab.bsky.social and @kevinbonham.com talk about glycoRNAs, and the way they're shielded from the immune system in a new paper from the labs of @raflynn5.bsky.social and @vijayrathinam.bsky.social 🧪
audiommunity.org/episodes/epi...
🚨New Paper in Cell 🧵🔎
Happy to share our work led by the @camilahcoelho.bsky.social, on mAbs against mpox.
We were very excited (and lucky!) to contribute to this collab. effort.
🦠“Human monoclonal antibodies targeting A35 protect from death caused by mpox”🦠
doi.org/10.1016/j.cell.2025.08.004
#InterferonPower! Thrilled for our latest work @cp-cell.bsky.social! With @danielboehmer.bsky.social, we dug into tons of papers & created what we hope will be a go-to resource for immunologists & non-immunologist about type I, II, III (& IV😉) #interferons! Free👉 authors.elsevier.com/a/1leKGL7PXu...
Thanks to Autoimmunity podcast @kevinbonham.bsky.social & @woodrufflab.bsky.social for discussing our glycoRNA paper w/ @raflynn5.bsky.social @vinnieviruses.bsky.social
I'm glad to see this being covered - because, frankly, this is a death-blow to collaborative science - however, the assumption of good faith in any of these decisions by reporters is mind-boggling.
This is happening for one reason - to assure top-down control of what gets funded and what does not.
Out today in Nature - our collaborative work with Ryan Flynn's lab, led by Dr. Peiyuan Chai with support from Dr. @sinakheiri.bsky.social and @shahjess.bsky.social from our group. Exciting findings showcasing how glycoRNAs can modulate angiogenesis!
Ivan Zanoni
Carolina Lucas
Science update from my postdoc Peiyuan Chai - his work “glycoRNA complexed with heparan sulfate regulates VEGF-A signaling” is now published @nature.com uncovering a new layer or glycoRNA-regulation of growth factor mediated control physiological processes rdcu.be/e1bBX
RFK Jr: We need to stop trusting the experts... Trusting the experts is not a feature of science or democracy, it's a feature of religion and totalitarianism.
In our latest episode, @woodrufflab.bsky.social and @kevinbonham.com talk about glycoRNAs, and the way they're shielded from the immune system in a new paper from the labs of @raflynn5.bsky.social and @vijayrathinam.bsky.social 🧪
audiommunity.org/episodes/epi...
Once in a while, we get the privilege to enjoy works like this:
www.science.org/doi/10.1126/...
Defense-associated reverse transcriptases (DRTs) are widespread bacterial anti-phage systems that use unconventional mechanisms of polynucleotide synthesis. We show that DRT3, which comprises two dist...
Science update from my postdoc Peiyuan Chai - his work “glycoRNA complexed with heparan sulfate regulates VEGF-A signaling” is now published @nature.com uncovering a new layer or glycoRNA-regulation of growth factor mediated control physiological processes rdcu.be/e1bBX
Ryan Flynn
Republicans Against Trumpism
Kurianlab
The US NIH is stepping back from 'top-down' science.
My latest analysis for @nature.com shows that funding calls have plummeted by 90%, funneling billions into broad, 'investigator-initiated' ideas, rather than targeted, agency-driven ones.
A massive shift for the American biomedical enterprise.
Ryan Flynn
US biomedical funding behemoth says the approach will boost innovation, but some researchers worry that understudied areas of science will suffer.
